Your request to link to rcsb for Retinoic acid receptor RXR-gamma


  • 1BY4: structure and mechanism of the homodimeric assembly of the rxr on dna (10.1006/JMBI.1999.3457 )
  • 1DKF: crystal structure of a heterodimeric complex of rar and rxr ligand- binding domains (10.1016/S1097-2765(00)80424-4 )
  • 1DSZ: structure of the rxr/rar dna-binding domain heterodimer in complex with the retinoic acid response element dr1 (10.1093/EMBOJ/19.5.1045 )
  • 1FBY: crystal structure of the human rxr alpha ligand binding domain bound to 9-cis retinoic acid (10.1093/EMBOJ/19.11.2592 )
  • 1FM6: the 2.1 angstrom resolution crystal structure of the heterodimer of the human rxralpha and ppargamma ligand binding domains respectively bound with 9-cis retinoic acid and rosiglitazone and co-activator peptides. (10.1016/S1097-2765(00)80448-7 )
  • 1FM9: the 2.1 angstrom resolution crystal structure of the heterodimer of the human rxralpha and ppargamma ligand binding domains respectively bound with 9-cis retinoic acid and gi262570 and co-activator peptides. (10.1016/S1097-2765(00)80448-7 )
  • 1G1U: the 2.5 angstrom resolution crystal structure of the rxralpha ligand binding domain in tetramer in the absence of ligand (10.1101/GAD.802300 )
  • 1G5Y: the 2.0 angstrom resolution crystal structure of the rxralpha ligand binding domain tetramer in the presence of a non-activating retinoic acid isomer. (10.1101/GAD.802300 )
  • 1K74: the 2.3 angstrom resolution crystal structure of the heterodimer of the human ppargamma and rxralpha ligand binding domains respectively bound with gw409544 and 9-cis retinoic acid and co-activator peptides. (10.1073/PNAS.241410198 )
  • 1MV9: crystal structure of the human rxr alpha ligand binding domain bound to the eicosanoid dha (docosa hexaenoic acid) and a coactivator peptide (10.1210/ME.16.5.987 )
  • 1MVC: crystal structure of the human rxr alpha ligand binding domain bound to the synthetic agonist compound bms 649 and a coactivator peptide (10.1210/ME.16.5.987 )
  • 1MZN: crystal structure at 1.9 angstroems resolution of the homodimer of human rxr alpha ligand binding domain bound to the synthetic agonist compound bms 649 and a coactivator peptide (10.1210/ME.16.5.987 )
  • 1R0N: crystal structure of heterodimeric ecdsyone receptor dna binding complex (10.1093/EMBOJ/CDG569 )
  • 1RDT: crystal structure of a new rexinoid bound to the rxralpha ligand binding doamin in the rxralpha/ppargamma heterodimer (10.1021/JM030565G )
  • 1RXR: high resolution solution structure of the retinoid x receptor dna binding domain, nmr, 20 structure (10.1006/JMBI.1998.1908 )
  • 1XDK: crystal structure of the rarbeta/rxralpha ligand binding domain heterodimer in complex with 9-cis retinoic acid and a fragment of the trap220 coactivator (10.1074/JBC.M409302200 )
  • 1XLS: crystal structure of the mouse car/rxr lbd heterodimer bound to tcpobop and 9cra and a tif2 peptide containg the third lxxll motifs (10.1016/J.MOLCEL.2004.11.036 )
  • 1XV9: crystal structure of car/rxr heterodimer bound with src1 peptide, fatty acid, and 5b-pregnane-3,20-dione. (10.1016/J.MOLCEL.2004.11.042 )
  • 1XVP: crystal structure of car/rxr heterodimer bound with src1 peptide, fatty acid and citco (10.1016/J.MOLCEL.2004.11.042 )
  • 1YNW: crystal structure of vitamin d receptor and 9-cis retinoic acid receptor dna-binding domains bound to a dr3 response element (10.1016/J.JSBMB.2004.03.084 )
  • 2ACL: liver x-receptor alpha ligand binding domain with sb313987 (10.1021/JM050532W )
  • 2GL8: human retinoic acid receptor rxr-gamma ligand-binding domain
  • 2NLL: retinoid x receptor-thyroid hormone receptor dna-binding domain heterodimer bound to thyroid response element dna (10.1038/375203A0 )
  • 2P1T: crystal structure of the ligand binding domain of the retinoid x receptor alpha in complex with 3-(2'-methoxy)- tetrahydronaphtyl cinnamic acid and a fragment of the coactivator tif-2 (10.1073/PNAS.0705356104 )
  • 2P1U: crystal structure of the ligand binding domain of the retinoid x receptor alpha in complex with 3-(2'-ethoxy)- tetrahydronaphtyl cinnamic acid and a fragment of the coactivator tif-2 (10.1073/PNAS.0705356104 )
  • 2P1V: crystal structure of the ligand binding domain of the retinoid x receptor alpha in complex with 3-(2'-propoxy)- tetrahydronaphtyl cinnamic acid and a fragment of the coactivator tif-2 (10.1073/PNAS.0705356104 )
  • 2ZXZ: crystal structure of the human rxr alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide (10.1002/CMDC.200900090 )
  • 2ZY0: crystal structure of the human rxr alpha ligand binding domain bound to a synthetic agonist compound and a coactivator peptide (10.1002/CMDC.200900090 )
  • 3A9E: crystal structure of a mixed agonist-bound rar-alpha and antagonist- bound rxr-alpha heterodimer ligand binding domains (10.1371/JOURNAL.PONE.0015119 )
  • 3E94: crystal structure of rxralpha ligand binding domain in complex with tributyltin and a coactivator fragment (10.1038/EMBOR.2009.8 )
  • 3FAL: humanrxr alpha & mouse lxr alpha complexed with retenoic acid and gsk2186 (10.1021/JM800612U )
  • 3FC6: hrxralpha & mlxralpha with an indole pharmacophore, sb786875 (10.1016/J.BMCL.2009.01.004 )
  • 3FUG: crystal structure of the retinoid x receptor ligand binding domain bound to the synthetic agonist 3-[4-hydroxy-3-(3,5, 5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)- phenyl]acrylic acid (10.1021/JM900096Q )
  • 3H0A: crystal structure of peroxisome proliferator-activated receptor gamma (pparg) and retinoic acid receptor alpha (rxra) in complex with 9-cis retinoic acid, co-activator peptide, and a partial agonist (10.1016/J.BMCL.2009.04.151 )
  • 3KWY: crystal structure of rxralpha ligand binding domain in complex with triphenyltin and a coactivator fragment (10.1007/S00018-009-0249-2 )
  • 3NSP: crystal structure of tetrameric rxralpha-lbd (10.1074/JBC.M110.166215 )
  • 3NSQ: crystal structure of tetrameric rxralpha-lbd complexed with antagonist danthron (10.1074/JBC.M110.166215 )
  • 3OAP: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 9-cis retinoic acid and the coactivator peptide grip-1 (10.1021/BI101288Y )
  • 3OZJ: crystal structure of human retinoic x receptor alpha complexed with bigelovin and coactivator src-1 (10.1016/J.JMB.2011.01.032 )
  • 3PCU: crystal structure of human retinoic x receptor alpha ligand-binding domain complexed with lx0278 and src1 peptide (10.1371/JOURNAL.PONE.0031811 )
  • 3R29: crystal structure of rxralpha ligand-binding domain complexed with corepressor smrt2 (10.1074/JBC.M111.245498 )
  • 3R2A: crystal structure of rxralpha ligand-binding domain complexed with corepressor smrt2 and antagonist rhein (10.1074/JBC.M111.245498 )
  • 3R5M: crystal structure of rxralphalbd complexed with the agonist magnolol (10.1371/JOURNAL.PONE.0028253 )
  • 3UVV: crystal structure of the ligand binding domains of the thyroid receptor:retinoid x receptor complexed with 3,3',5 triiodo-l- thyronine and 9-cis retinoic acid (10.1073/PNAS.1119852109 )
  • 4CN2: crystal structure of the human retinoid x receptor dna- binding domain bound to the human ramp2 response element (10.1038/SREP08216 )
  • 4CN3: crystal structure of the human retinoid x receptor dna- binding domain bound to the human gde1spa response element (10.1038/SREP08216 )
  • 4CN5: crystal structure of the human retinoid x receptor dna- binding domain bound to the human nr1d1 response element (10.1038/SREP08216 )
  • 4CN7: crystal structure of the human retinoid x receptor dna- binding domain bound to an idealized dr1 response element (10.1038/SREP08216 )
  • 4J5W: crystal structure of the apo-pxr/rxralpha lbd heterotetramer complex (10.1016/J.JMB.2013.04.012 )
  • 4J5X: crystal structure of the sr12813-bound pxr/rxralpha lbd heterotetramer complex (10.1016/J.JMB.2013.04.012 )
  • 4K4J: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 9cuab30 and the coactivator peptide grip-1 (10.1074/JBC.M113.476861 )
  • 4K6I: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with targretin and the coactivator peptide grip-1 (10.1074/JBC.M113.476861 )
  • 4M8E: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with (s) 4-methyl 9cuab30 coactivator peptide grip-1 (10.1016/J.BMC.2013.11.039 )
  • 4M8H: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with (r)4-methyl 9cuab30 and coactivator peptide grip- 1 (10.1016/J.BMC.2013.11.039 )
  • 4N5G: crystal structure of rxra lbd complexed with a synthetic modulator k8012 (10.1016/J.CHEMBIOL.2014.02.017 )
  • 4N8R: crystal structure of rxra lbd complexed with a synthetic modulator k- 8008 (10.1016/J.CHEMBIOL.2014.02.017 )
  • 4OC7: retinoic acid receptor alpha in complex with (e)-3-(3'-allyl-6- hydroxy-[1,1'-biphenyl]-3-yl)acrylic acid and a fragment of the coactivator tif2 (10.1002/ANIE.201403773 )
  • 4POH: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 8-methyl uab30 and the coactivator peptide grip-1 (10.1021/JM5004792 )
  • 4POJ: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 7-methyl uab30 and the coactivator peptide grip-1 (10.1021/JM5004792 )
  • 4PP3: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 6-methyl uab30 and the coactivator peptide grip-1 (10.1021/JM5004792 )
  • 4PP5: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 5-methyl uab30 and the coactivator peptide grip-1 (10.1021/JM5004792 )
  • 4RFW: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 9cuab70 and the coactivator peptide grip-1 (10.1021/ACS.JMEDCHEM.5B00829 )
  • 4RMC: crystal structure of human retinoid x receptor alpha-ligand binding domain complex with 9cuab76 and the coactivator peptide grip-1 (10.1021/ACS.JMEDCHEM.5B00829 )
  • 4RMD: crystal structure of human retinoid x receptor alpha ligand binding domain complex with 9cuab110 and coactivator peptide grip-1 (10.1021/ACS.JMEDCHEM.5B00829 )
  • 4RME: crystal structure of human retinoid x receptor alpha ligand binding domain complex with 9cuab111 and coactivator peptide grip-1 (10.1021/ACS.JMEDCHEM.5B00829 )
  • 4ZO1: crystal structure of the t3-bound tr-beta ligand-binding domain in complex with rxr-alpha (10.1038/NCOMMS9013 )
  • 4ZSH: rxr lbd in complex with 9-cis-13,14-dihydroretinoic acid (10.1371/JOURNAL.PGEN.1005213 )
  • 5EC9: retinoic acid receptor alpha in complex with chiral dihydrobenzofuran benzoic acid 9a and a fragment of the coactivator tif2 (10.1021/ACS.JMEDCHEM.5B01702 )
  • 5JI0: ppargamma-rxralpha(s427f) heterodimer in complex with src-1, rosiglitazone, and 9-cis-retanoic acid
  • 5LYQ: crystal structure of the retinoic acid receptor alpha in complex with a synthetic spiroketal agonist and a fragment of the tif2 co- activator. (10.1002/ANIE.201612504 )
  • 5MJ5: crystal structure of the retinoid x receptor alpha in complex with synthetichonokiol derivative 3 and a fragment of the tif2 co- activator. (10.1021/ACSCHEMNEURO.7B00216 )
  • 5MK4: crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 7 and a fragment of the tif2 co- activator. (10.1021/ACSCHEMNEURO.7B00216 )
  • 5MKJ: crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 9 and a fragment of the tif2 co- activator. (10.1021/ACSCHEMNEURO.7B00216 )
  • 5MKU: crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 4 and a fragment of the tif2 co- activator. (10.1021/ACSCHEMNEURO.7B00216 )
  • 5MMW: crystal structure of the retinoid x receptor alpha in complex with synthetic honokiol derivative 6 and a fragment of the tif2 co- activator. (10.1021/ACSCHEMNEURO.7B00216 )
  • 5TBP: crystal structure of rxr-alpha ligand binding domain complexed with synthetic modulator k8003 (10.1038/NCOMMS16066 )
  • 5Z12: a structure of fxr/rxr (10.1074/JBC.RA118.004188 )
  • 5ZQU: crystal structure of tetrameric rxralpha-lbd complexed with partial agonist cbt-pmn (10.1002/1873-3468.13301 )
  • 6A5Y: crystal structure of human fxr/rxr-lbd heterodimer bound to hnc143 and 9cra and src1 (10.1074/JBC.RA118.004652 )
  • 6A5Z: crystal structure of human fxr/rxr-lbd heterodimer bound to hnc180 and 9cra and src1 (10.1074/JBC.RA118.004652 )
  • 6A60: crystal structure of human fxr/rxr-lbd heterodimer bound to gw4064 and 9cra and src1 (10.1074/JBC.RA118.004652 )
  • 6FBQ: crystal structure of the human retinoid x receptor dna-binding domain bound to the human mep dr1 response element, ph 7.0 (10.1016/J.MCE.2018.11.008 )
  • 6FBR: crystal structure of the human retinoid x receptor dna-binding domain bound to the human mep dr1 response element, ph 4.2 (10.1016/J.MCE.2018.11.008 )
  • 6JNO: rxra structure complexed with cu-6pmn (10.1021/ACS.JMEDCHEM.9B00995 )
  • 6JNR: rxra structure complexed with cu-6pmn and src1 peptide.
  • 6L6K: crystal structure of dimeric rxralpha-lbd complexed with partial agonist cbt-pmn and src1
  • 6LB4: crystal structure of dimeric rxr-lbd complexed with net-3me and tif2 co-activator
  • 6LB5: crystal structure of dimeric rxr-lbd complexed with full agonist net- 3ib and tif2 co-activator
  • 6LB6: crystal structure of dimeric rxr-lbd complexed with partial agonist net-4ib and tif2 co-activator
  • 6SJM: crystal structure of the retinoic acid receptor alpha in complex with compound 24 (jp175) (10.1021/ACSMEDCHEMLETT.9B00306 )
  • 6STI: crystal structure of rxralpha lbd in complex with lg 100754 and a coactivator peptide (10.3390/CELLS8111392 )
  • 6XWG: crystal structure of the human rxr/rar dna-binding domain heterodimer bound to the human rarb2 dr5 response element (10.1093/NAR/GKAA697 )
  • 6XWH: crystal structure of the human rxr dna-binding domain homodimer bound to the human hoxb13 dr0 response element (10.1093/NAR/GKAA697 )
  • 7A77: crystal structure of rxr alpha lbd in complexes with palmitic acid and grip-1 peptide (10.3390/IJMS21228457 )
  • 7A79: crystal structure of rxr gamma lbd in complexes with palmitic acid and grip-1 peptide (10.3390/IJMS21228457 )
  • 7AOS: crystal structure of the raralpha/rxralpha ligand binding domain heterodimer in complex with a fragment of src1 coactivator (10.1016/J.JMB.2021.166899 )
  • 7B88: crystal structure of retinoic acid receptor alpha (rxra) in complexed with s99 inhibitor (10.1021/ACS.JMEDCHEM.1C00235 )
  • 7B9O: crystal structure of retinoic acid receptor alpha (rxra) in complexed with s169 inhibitor (10.1021/ACS.JMEDCHEM.1C00235 )
  • 7BK4: crystal structure of rxralpha ligand binding domain in complex with a fragment of the tif2 coactivator (10.1016/J.JMB.2021.166899 )
  • 7CFO: crystal structure of human rxralpha ligand binding domain complexed with cbtf-ee. (10.1021/ACS.JMEDCHEM.0C01354 )
  • 7NKE: crystal structure of human rxralpha ligand binding domain in complex with 2,4-di-tert-butylphenol and a coactivator fragment